Business
BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced financial results for the fourth quarter and full year 2025, and introduced 2026 financial guidance.
About this update from Biolife Solutions, Inc.
[{"type":"text","content":"Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year","length":168,"tagName":"p","attribs":{}},{"type":"text","content":"GAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarter","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"GAAP net income of $2.1 million or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarter","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"Expects 2026 revenue growth of $112.5 million to $115.0 million, up 17%-20% over 2025","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call begins at 4:30 p.m. Eastern time today","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"BOTHELL, Wash., Feb. 26, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced financial results for the fourth quarter and full year 2025, and introduced 2026 financial guidance.","length":388,"tagName":"p"},{"type":"image","alt":"BioLife Solutions Logo (PRNewsfoto/BioLife Solutions, Inc.)","displaySize":"","headline":null,"caption":"BioLife Solutions Logo (PRNewsfoto/BioLife Solutions, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":111,"url":"https://media.zenfs.com/en/prnewswire.com/2c77b8327844a4e269c45c61c477e453"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dk9sWRfYQGFiZfYvs0ludw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2c77b8327844a4e269c45c61c477e453","width":400,"height":111}},"href":"https://mma.prnewswire.com/media/2827727/BioLife_Solutions__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""2025 was a transformative year for BioLife. We delivered 29% revenue growth, led by sustained strength in our biopreservation media franchise and completed a strategic divestiture that firmly established BioLife as a focused, pure-play cell processing company centered on high-value, recurring revenu...